Log In
BCIQ
Print this Print this
 

PepVax

  Manage Alerts
Collapse Summary General Information
Company Fortress Biotech Inc.
DescriptionPeptide vaccine with human cytomegalovirus (CMV) phosphoprotein 65 (pp65; UL183) antigen combined with a toll-like receptor 9 (TLR9) agonist
Molecular Target Toll-like receptor 9 (TLR9) ; Human cytomegalovirus (CMV) phosphoprotein 65 (pp65) (UL83)
Mechanism of ActionVaccine; Toll-like receptor 9 (TLR9) agonist
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationCytomegalovirus (CMV)
Indication DetailsPrevent cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant and solid organ transplant recipients
Regulatory Designation
PartnerCity of Hope

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$100.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/02/2015

$100.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today